A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination | Synapse
March 3, 2026
A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination
Key Points
Recurrent glioblastoma patients showed responses to tremelimumab and durvalumab treatment, indicating a possible positive effect.
The study highlighted significant outcomes based on a phase 2 clinical trial involving a novel therapy combination.
An open-label design allowed direct evaluation of treatment efficacy in participants without a placebo.
Further studies may be needed to fully confirm the clinical benefits and identify long-term effects of this combination therapy.